Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBIT Margin (2016 - 2026)

Cytosorbents filings provide 15 years of EBIT Margin readings, the most recent being 92.68% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 12978.0% to 92.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.87%, a 4134.0% increase, with the full-year FY2025 number at 4.87%, up 4135.0% from a year prior.
  • EBIT Margin hit 92.68% in Q4 2025 for Cytosorbents, up from 30.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 92.68% in Q4 2025 to a low of 111.17% in Q3 2022.
  • Median EBIT Margin over the past 5 years was 55.73% (2021), compared with a mean of 56.44%.
  • Biggest five-year swings in EBIT Margin: crashed -6665bps in 2021 and later soared 12978bps in 2025.
  • Cytosorbents' EBIT Margin stood at 88.68% in 2021, then rose by 24bps to 67.69% in 2022, then plummeted by -60bps to 108.54% in 2023, then soared by 66bps to 37.1% in 2024, then surged by 350bps to 92.68% in 2025.
  • The last three reported values for EBIT Margin were 92.68% (Q4 2025), 30.17% (Q3 2025), and 37.59% (Q2 2025) per Business Quant data.